STRATA Skin Sciences, Inc. · OTC:SSKN
STRATA Skin Sciences — Investor Presentation (August 2019)
26 slides from STRATA Skin Sciences's investor presentation, Aug 7, 2019
Slide 1: August 2019 Investor Presentation
August 2019 Investor Presentation Driving Value to Dermatology Partners Matching Patients with Clinics
Slide 2: Safe Harbor Statement
This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking s
Slide 3: STRATA Investment Highlights
STRATA Investment Highlights 3 A Win-Win-Win CompanyFor patients – safest, most effective, no side effectsFor clinics – stable increased revenue baseFor Payers – the least expensive treatment availableExcimer Laser Technology for Dermatology IndicationsPsoriasis, Vitiligo, Atopic Dermatitis and Leuk
Slide 4: Excimer laser use grew at ~30% annual rate in the US over last 15 years
Excimer laser use grew at ~30% annual rate in the US over last 15 years 4 Historical phototherapy utilization. Trend in phototherapy utilization among Medicare beneficiaries by billing code across all providers, 2000 to 2015. HCPCS, Healthcare Common Procedure Coding System; PUVA, psoralen plus ultr
Slide 5: Continuous technology investment and business growth
Continuous technology investment and business growth 510 (K) FDA Approval AL-7000 Ultra Velocity 400 Velocity 700 Velocity 7 Series S3 2000 2005 2008 2010 2014 2018 CPT code Approval DTC platform creation 510 (K) FDA Approval (MMD)* Full Insurance Reimbursement 2012 *MMD tip is a diagnostic accessor
Slide 6: XTRAC is to excimer what Xerox is to photocopy
XTRAC® is to excimer what Xerox is to photocopy Over 150 peer-reviewed published clinical-studiesMultiple academic institutes in U.S. use XTRAC Over 2,200 device installed base worldwideOver 1,000 dermatology practices in the U.S. have XTRAC, providing device access to over 3,000 dermatology provide
Slide 7: Partner academic institutes
Partner academic institutes 7
Slide 8: How XTRAC Works - Psoriasis
How XTRAC Works - Psoriasis After 4 tx After 2 tx Baseline Beam of UVB light applied to the affected area UVB light induces apoptosis of the keratinocytes and T cells in the dermis Promotes immunosuppression Induces alterations in cytokine profile 150+ peer reviewed published clinical studies 8 PASI
Slide 9: How XTRAC Works - Vitiligo
How XTRAC Works - Vitiligo 9 Long-term skin condition characterized by patches of skin losing its pigment Disease is believed to be due to genetic susceptibility where the autoimmune disease is then triggeredPotentially the immune system is attacking and destroying melanocytes of the skinLife-alteri
Slide 10: Domestic XTRAC Revenue Funnel
Domestic XTRAC Revenue Funnel REOCCURRENCE DTC ADVERTISING ASSIGNING A DOCTOR PARTNER PATIENTAPPOINTMENT TREATMENT WIN WIN WIN DOCTOR PATIENT STRATA (AND PAYER) INTEREST CREATION IN-HOUSE CALL CENTER INSURANCE ADVOCACY VERIFY APPOINTMENTPrescription of treatment VERIFY XTRACTREATMENT 10 Patient lead
Slide 11: DTC advertisement is generating word of mouth
DTC advertisement is generating word of mouth for XTRAC through ‘Shares’ and ‘Comments’ 11
Slide 12: XTRAC helps patients Live Clear, Live Free
XTRAC helps patients Live Clear, Live Free… https://youtu.be/GdMBliZYy70 12
Slide 13: International Market: Installed Base
International Market: Installed Base Major Markets – China, Japan, Saudi Arabia, South KoreaInsurance covered in most marketsUsage/device higher than domestic market – untapped potential in U.S.1,300 OUS devices sold and in servicePlacement Recurring revenue model agreement executed for South Korea
Slide 14: XTRAC adds recurring revenue driver for its partners
XTRAC adds (delegated) recurring revenue driver for its partners CPT CODE Description 2018 National AverageMedicare Payment Rate 96920 Laser treatment for inflammatory skin diseases, (psoriasis); total area less than 250 sq cm $168.12 96921 Laser treatment for inflammatory skin diseases, (psoriasis)
Slide 15: Domestic Market: Installed Base - sales and service engine
Domestic Market: Installed Base – sales and service engine Overview 764 Partner XTRAC clinics 150+ sold XTRAC 4 Regions 24 Sales Territories 15 Field Service Techs In-house call center to qualify leadsOnly one competitor in U.S. 15 Territories color coded
Slide 16: Financial Metrics - recurring revenue and margin growth
Financial Metrics – recurring revenue and margin growth 16 Note: all quarterly numbers are unaudited
Slide 17: Install Base Growth Drivers
Install Base Growth Drivers 17 1,608 clinics owned by 58 roll-up groups164 (10.2%) of which are XTRAC partnersStrata signs strategic expansion agreements with major groups Expansion into roll-up groups Comebacks 300-400 Clinics own Excimer lasers Conversion to an XTRAC partner clinic = immediate rev
Slide 18: Recent Financial Highlights
Recent Financial Highlights Q2 2019Q1 2019 18 Total Revenue $7.4 million +15% versus Q1 2018 Recurring XTRAC Revenue $5.3 million +17% versus Q1 2018 Gross Margin 62% +13% versus Q1 2018 Recurring XTRAC Margin 66% +9% versus Q1 2018 Cash and Cash Equivalents $16.4 million Total Revenue $8.2 million
Slide 19: Financial Profile
Financial Profile Shares and Share Equivalents – Market cap*- $91M (As of July 29, 2019) * On an as converted basis of the convertible preferred stock** Does not include 750K warrants with a weighted average exercise price of $4.12 as of July 30, 2019 of which 600K expire by June 2020** Does not inc
Slide 20: STRATA Investment Highlights
STRATA Investment Highlights 20 A Win-Win-Win CompanyFor patients – safest, most effective, no side effectsFor clinics – stable increased revenue baseFor Payers – the least expensive treatment availableExcimer Laser Technology for Dermatology IndicationsPsoriasis, Vitiligo, Atopic Dermatitis and Leu
Slide 21: August 2019 Driving Value to Dermatology Partners
August 2019 Investor Presentation Driving Value to Dermatology Partners Matching Patients with Clinics 21
Slide 22: Appendix
Appendix 22
Slide 23: Sample studies from 150+ clinical studies
Multicenter Psoriasis Study1 Scalp Study3 124 patients were enrolled and 80 completed the protocol. 72% achieved at least 75% clearing in an average of 6.2 treatments. 84% of patients reached improvement of 75% or better after 10 or fewer treatments. 50% of patients reached improvement of 90% or bet
Slide 24: Maximizing Dermatologist Partner Clinical Revenue
Maximizing Dermatologist Partner Clinical Revenue Data collected directly from the lasers demonstrates the importance of following treatment guidelines Revenue = # of lasers x # of treatments/pt x # patients x cost/tx x recurrence factor 24
Slide 25: Proven Turnaround Strategy - Install Base and Utilization Growth
Proven Turnaround Strategy – Install Base and Utilization Growth STRATA bought XTRAC business from PhotoMedex in 2015 25 Note the numbers prior to Jan 1, 2018 do not reflect adjustments for the adoption of ASC 606 Q2 ’19 average revenue – 13% growth over Q2‘18
Slide 26: DTC - The Driver for Recurring Revenue Growth
DTC – The Driver for Recurring Revenue Growth 26 Q2 ’19 qtr. revenue - 15% growth over Q2 ‘18 STRATA bought XTRAC business from PhotoMedex in 2015 Note the numbers prior to Jan 1, 2018 do not reflect adjustments for the adoption of ASC 606
STRATA Skin Sciences — Investor Presentation (August 2019) on 6ix